Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The new collaboration combines MD Anderson’s unique understanding of potential drivers of PDAC with Boehringer Ingelheim’s experience in drug discovery and development.

  • New data from a completed phase 3 trial show Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1c (A1C) from baseline after 24 weeks of treatment. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. These data, from the Trulicity AWARD-8 clinical trial, were presented for the first time today at the 2015 International Diabetes Federation (IDF) World Diabetes Congress in Vancouver, Canada.

  • TAKE Solutions launched PV India, a unique pharmacovigilance peer network, organized and managed by one of TAKE’s Life Sciences division, Navitas. At the time when the pharma industry is facing business challenges and the government of India citing delayed regulatory approvals as a primary concern, it is imperative for Pharma companies to arrive at solutions to tackle these problems.

  • Quantum Pharma Plc, the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a further three out-licensing deals in Germany, though Lamda (UK) Limited, Lamda Laboratories SA and Lamda Pharmaceuticals SA (collectively ‘Lamda’), part of its Niche Pharmaceutical division.  These agreements form part of the core strategy for this division.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vasomera (PB1046) Injection for the treatment of cardiomyopathy associated with dystrophinopathies: Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy (XL-dCMP).

  • Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that on November 30, 2015 the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Kevetrin for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye.

  • Researchers have developed two antibodies to potentially treat or prevent pertussis, the highly contagious respiratory tract infection that affects millions of infants and results in an estimated 200,000 child deaths every year.

  • Indian scientists have developed a cheap, easy and ultra-sensitive blood-based strip test for kala-azar or visceral leishmaniasis (VL), the second largest parasitic killer in the world after malaria. Having been validated in India, Nepal, Sri Lanka and Brazil, the technology will now be tested in Africa to enable nations fight the ravages of the disease that is lethal if untreated.

Subscribe to Pharma News